Histone deacetylase inhibitors and proteasome inhibitor are all emerging as new classes of anticancer agents. We chose TSA and PS-341 to identify whether they have a synergistic efficacy on human ovarian cancer cells. After incubated with 500 nM TSA or/and 40 nM PS-341, we found that combined groups resulted in a striking increase of apoptosis and G2/M blocking rates, no matter in A2780, cisplatin-sensitive ovarian cancer cell line OV2008 or its resistant variant C13**. This demonstrated that TSA interacted synergistically with PS-341, which raised the possibility that combined the two drugs may represent a novel strategy in ovarian cancer.</.
基金：
National Science Foundation of China [30770914, 30801224, 30770913, 30700895]; "973" Program [2009CB521808]; Major Innovation Medicine program [2009ZX09103-738, 2009ZX09103-739, 2009ZX09103-740]
第一作者单位：[1]Huazhong Univ Sci & Technol,Canc Biol Ctr,Tongji Hosp,Tongji Med Coll,Wuhan 430030,Hubei,Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Fang Yong,Hu Yi,Wu Peng,et al.Synergistic Efficacy in Human Ovarian Cancer Cells by Histone Deacetylase Inhibitor TSA and Proteasome Inhibitor PS-341[J].CANCER INVESTIGATION.2011,29(4):247-252.doi:10.3109/07357907.2010.496756.
APA：
Fang, Yong,Hu, Yi,Wu, Peng,Wang, Beibei,Tian, Yuan...&Meng, Li.(2011).Synergistic Efficacy in Human Ovarian Cancer Cells by Histone Deacetylase Inhibitor TSA and Proteasome Inhibitor PS-341.CANCER INVESTIGATION,29,(4)
MLA：
Fang, Yong,et al."Synergistic Efficacy in Human Ovarian Cancer Cells by Histone Deacetylase Inhibitor TSA and Proteasome Inhibitor PS-341".CANCER INVESTIGATION 29..4(2011):247-252
